Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
Crossref DOI link: https://doi.org/10.1007/s10549-017-4592-y
Published Online: 2017-11-29
Published Print: 2018-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yu, Y. F.
Wang, Y.
Fu, T. P.
Chen, K.
Liu, J. Q.
Yao, H. R. http://orcid.org/0000-0003-2579-6220
License valid from 2017-11-29